New Drug Brings Hope to Muscular Dystrophy

Sarepta Therapeutics, a Cambridge based biotechnology company, is preparing to submit a new drug to the Food and Drug Administration in the first half of 2014. Shares in the company stock rose 13% in pre-market trading after the announcement. The drug, called eteplirsen, showed encouraging results in a 12 patient trial conducted earlier this year […]
Continue reading